IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Alphamab Oncology IPO Initiation: Clear Diagnosis

Alphamab Oncology IPO: Valuation Easy to Swallow

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/alphamab-co-ltd" target="_blank" data-smartkarma-citation="entities:28213:1" rel="noopener">Alphamab Co Ltd (9966 HK)</a> is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of biologics for oncology.  Alphamab will commence trading on Thursday, 12 December. Alphamab priced its IPO at HK$10.20 per share (at the top-end of the range). </p><div class="content-highlight"><p>In <a href="https://www.smartkarma.com/insights/alphamab-oncology-ipo-valuation-easy-to-swallow" target="_blank" rel="noopener">our valuation note</a>, we noted that the combination of strong cornerstone support and a reasonable valuation makes Alphamab tempting up to the mid-point of the pricing range.  Our rNPV-based scenario analysis suggests that at the IPO price, Alphamab is fully priced.</p></div>

Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of biologics for oncology.  Alphamab will commence trading on Thursday, 12 December. Alphamab priced its IPO at HK$10.20 per share (at the top-end of the range). In our valuation note, we noted that the combination of strong cornerstone support and a reasonable valuation makes Alphamab tempting up to the mid-point of the pricing range.  Our rNPV-based scenario analysis suggests that at the IPO price, Alphamab is fully priced.

Alphamab Oncology: Trading Debut, Valuation Scenario Analysis